SEC Filing Summary: India Globalization Capital, Inc. (IGC Pharma, Inc.)
Business Context and Reporting Period
This Form 8-K was filed on April 5, 2012, by India Globalization Capital, Inc. (also referenced as IGC Pharma, Inc.). The report discloses a specific corporate event regarding debt management that occurred on the same date.
Key Financial Metrics
- Debt Reduction: The Company retired a note with a principal balance of $2,232,627.79.
- Interest Savings: Management projects an annual reduction in interest costs of approximately $612,000.
- Revenue and Profit: The filing text does not provide a clear value for revenue, net income, or operating margins.
- Cash Flow and Liquidity: The filing text does not provide a clear value for total cash flow or current liquidity ratios.
Material Changes
The primary material change is the elimination of a specific debt obligation. This action directly reduces the Company's outstanding liabilities and future interest expense obligations compared to the prior period.
Outlook and Management Commentary
Management highlighted the retirement of the note as a strategic move to lower the cost of capital. The projected $612,000 annual interest savings indicates an improved future earnings profile, assuming no offsetting increases in other expenses. No specific forward-looking revenue guidance or new risk factors were disclosed in this report.
Investor Verification Checklist
- Verify the source of funds used to retire the $2.23 million note (e.g., cash on hand, new financing, or asset sale).
- Confirm the total remaining debt load and weighted average interest rate post-retirement.
- Review the attached press release (Exhibit 99.1) for additional context on the note's terms.
- Assess the impact of the $612,000 interest savings on the Company's projected EBITDA for the fiscal year.